BIOCHROMIX.COM
BioChromix NewCoOCTOBER 2, 2014: Cadila Pharmaceuticals Sweden AB acquires BioChromix NewCo AB PRESS RELEASE(PDF). A drug that could influence the underlying disease mechanism would have fundamental economical and societal impact across the world. The company is continuing to develop, optimize and validate lead compounds both in vitro and in vivo in the field of neurodegenerative diseases. Org nr. 556949-3280.
http://www.biochromix.com/


